title: [Mutagenic effects of coal tar used in the treatment of psoriasis].
abstract: BACKGROUND
  Pharmaceutic tar used in the treatment of psoriasis has a high contents of polycyclic aromatic carbohydrates which are considered to be carcinogenic.
  
  
  OBJECTIVE
  The study is aimed at the estimation of the genotoxic risk arising from the treatment of psoriatic patients by pharmaceutic tar. The estimation is performed by biomonitoring.
  
  
  METHODS
  The used methods included: bacterial test on TA 98 strain of Salmonella typhimurium aimed at the assessment of mutagenity of urine and cytogenetic test aimed at the assessment of chromosomal aberrations in peripheral lymphocytes.
  
  
  RESULTS
  The exposition of psoriatic patients to pharmaceutic tar significantly increased the index of mutagenity as an index of the presence of mutagen in urine, as well as the occurrence of chromosomal aberrations in peripheral lymphocytes.
  
  
  CONCLUSIONS
  The results of monitoring have indicated that psoriatic patients treated by pharmaceutic tar are endangered by an increased genotoxic risk. (Tab. 2, Ref. 17.)
authors.affiliation: Ustav lekárskej biológie LF UPJS, Kosice, Slovakia.
authors.forename: D
authors.initials: D
authors.lastname: Gardosová
authors.forename: V
authors.initials: V
authors.lastname: Mezencevová
authors.forename: I
authors.initials: I
authors.lastname: Kalina
authors.forename: F
authors.initials: F
authors.lastname: Hejj
authors.forename: M
authors.initials: M
authors.lastname: Kopka
authors.forename: J
authors.initials: J
authors.lastname: Petrovicová
mesh_terms: D000328:Adult; D003033:Coal Tar / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007641:Keratolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D009152:Mutagenicity Tests; D009153:Mutagens; D011565:Psoriasis / Q000188:drug therapy*
chemical_list: D007641:Keratolytic Agents; D009153:Mutagens; D003033:Coal Tar